Phibro Animal Health (NASDAQ:PAHC) Cut to Hold at Zacks Research

Zacks Research lowered shares of Phibro Animal Health (NASDAQ:PAHC) from a strong-buy rating to a hold rating in a report released on Monday morning,Zacks.com reports.

A number of other research firms have also weighed in on PAHC. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. JPMorgan Chase & Co. raised their target price on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $37.50.

Phibro Animal Health Price Performance

PAHC opened at $51.52 on Monday. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The company has a market cap of $2.09 billion, a P/E ratio of 22.90, a P/E/G ratio of 0.79 and a beta of 0.80. The company has a 50 day moving average of $40.75 and a two-hundred day moving average of $38.84. Phibro Animal Health has a 52-week low of $16.16 and a 52-week high of $56.30.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.18. The firm had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, analysts expect that Phibro Animal Health will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be issued a $0.12 dividend. This represents a $0.48 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Wednesday, March 4th. Phibro Animal Health’s payout ratio is currently 21.33%.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 14,184 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $51.62, for a total transaction of $732,178.08. Following the transaction, the chief executive officer owned 50,760 shares of the company’s stock, valued at $2,620,231.20. This trade represents a 21.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 285,120 shares of company stock worth $13,340,648 in the last 90 days. Corporate insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after purchasing an additional 546 shares during the period. Millennium Management LLC lifted its position in shares of Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Phibro Animal Health by 65.3% in the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after buying an additional 13,404 shares during the period. Yousif Capital Management LLC bought a new stake in shares of Phibro Animal Health during the 2nd quarter valued at about $200,000. Finally, Envestnet Asset Management Inc. raised its stake in Phibro Animal Health by 97.3% during the second quarter. Envestnet Asset Management Inc. now owns 24,334 shares of the company’s stock worth $621,000 after acquiring an additional 11,999 shares during the period. 99.34% of the stock is owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.